Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Pulm Circ ; 14(2): e12395, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38887742

ABSTRACT

Data on demographic characteristics and therapeutic approaches in Latin American pulmonary arterial hypertension (PAH) patients are scarce. Pulmonary Hypertension Mexican registry (REMEHIP) is a multicenter Mexican registry of adult and pediatric patients, including prevalent and incident cases. Objective: assess clinical characteristics, treatment trends, and in-hospital outcomes. Inclusion: age >2 years, diagnosis of pulmonary hypertension (PH) (groups 1 and 4), right heart catheterization with mPAP ≥25 mmHg, PWP ≤ 15 mmHg, and PVR > 3 Wood unit (WU). We included 875 PH patients, 619 adults, 133 pediatric idiopathic PAH (IPAH), and 123 chronic thromboembolic pulmonary hypertension (CTEPH) patients. We enrolled 48.4% of the incident and 51.6% of the prevalent adult and pediatric patients. PAH adults: age 43 ± 15, females 81.9%, functional class (FC) (I/II) 66.5%, 6-min walk distance (6MWD) 378 ± 112 m, mPAP 57.3 ± 19.0 mmHg, confidence interval (CI) 3.3 ± 1.5 L/min/m2, PVR 12.0 ± 8.1 WU. PAH pediatrics: age 9 ± 5, females 51.1%, FC (I/II) 85.5%, 6MWD 376 ± 103 m, mPAP 49.7 ± 13.4 mmHg, CI 2.6 ± 0.9 L/min/m2, PVR 16.4 ± 13.5 WU. CTEPH: age 44 ± 17, females 56.1%, FC (I/II) 65.5%, 6MWD 369 ± 126 m, mPAP 49.7 ± 13.4 mmHg, CI 2.6 ± 0.9 L/min/m2, PVR 10.5 + 6.5 WU. When we analyzed the IPAH group separately, it sustained a high functional class I/II incidence. REMEHIP shows better functional class in young females with severe PAH than in American and European patients. Also, PAH pediatric patients had a better functional class than other registries. However, our registry also shows that our population's access to specific pharmacologic treatments is still far from optimal.

4.
J Comp Eff Res ; 10(16): 1251-1257, 2021 11.
Article in English | MEDLINE | ID: mdl-34585624

ABSTRACT

Aim: The objective of this study was to evaluate the healthcare costs and resource utilization of pediatric pulmonary arterial hypertension management at a third-level hospital in Mexico. Methods: A retrospective cohort study was conducted in a pediatric population with pulmonary arterial hypertension. Only direct medical costs, derived from pharmacological treatment, laboratory tests, physician visits and hospitalizations, were considered. From an institutional perspective, all costs were accounted for in 2019 US dollars. Results: A total of 82 patients were included. Of these, 55% were female and the mean age was 6.9 (standard deviation ± 4) years. The mean annual cost was $17,452.14 (standard deviation ± $38,944.10), with a median cost of $8832.75. Conclusion: Pulmonary arterial hypertension is a costly disease, with hospitalization and pharmacological treatment being areas with a higher economic burden. Functional class IV has greater resource utilization and costs.


Subject(s)
Pulmonary Arterial Hypertension , Child , Female , Health Care Costs , Hospitals , Humans , Mexico , Retrospective Studies
5.
Arch Cardiol Mex ; 91(Suplemento COVID): 040-046, 2021 Dec 20.
Article in Spanish | MEDLINE | ID: mdl-33651785

ABSTRACT

We present an institutional guide for a referral to the specialized care center and initial management of pediatric patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe manifestations of pediatric inflammatory multisystemic syndrome or symptoms similar to Kawasaki syndrome, and who must have a multidisciplinary approach to ensure adequate treatment and safety for the team of Health.


Presentamos una guía para la referencia al centro de atención especializada y el manejo inicial de pacientes pediátricos infectados por el coronavirus 2 del síndrome respiratorio agudo grave (SARS-CoV-2) con manifestaciones graves del síndrome multisistémico inflamatorio pediátrico o síntomas semejantes al síndrome de Kawasaki y que deben tener un abordaje multidisciplinario para garantizar un adecuado tratamiento y la mayor seguridad para el equipo de salud.


Subject(s)
COVID-19 , Mucocutaneous Lymph Node Syndrome , Referral and Consultation , COVID-19/complications , Cardiology , Child , Humans , Mucocutaneous Lymph Node Syndrome/therapy , Mucocutaneous Lymph Node Syndrome/virology , SARS-CoV-2
6.
J Clin Lipidol ; 15(1): 124-133, 2021.
Article in English | MEDLINE | ID: mdl-33422452

ABSTRACT

BACKGROUND: Familial hypercholesterolemia (FH) remains underdiagnosed and undertreated. OBJECTIVE: Report the results of the first years (2017-2019) of the Mexican FH registry. METHODS: There are 60 investigators, representing 28 federal states, participating in the registry. The variables included are in accordance with the European Atherosclerosis Society (EAS) FH recommendations. RESULTS: To date, 709 patients have been registered, only 336 patients with complete data fields are presented. The mean age is 50 (36-62) years and the average time since diagnosis is 4 (IQR: 2-16) years. Genetic testing is recorded in 26.9%. Tendon xanthomas are present in 43.2%. The prevalence of type 2 diabetes is 11.3% and that of premature CAD is 9.8%. Index cases, male gender, hypertension and smoking were associated with premature CAD. The median lipoprotein (a) level is 30.5 (IQR 10.8-80.7) mg/dl. Statins and co-administration with ezetimibe were recorded in 88.1% and 35.7% respectively. A combined treatment target (50% reduction in LDL-C and an LDL-C <100 mg/dl) was achieved by 13.7%. Associated factors were index case (OR 3.6, 95%CI 1.69-8.73, P = .002), combination therapy (OR 2.4, 95%CI 1.23-4.90, P = .011), type 2 diabetes (OR 2.8, 95%CI 1.03-7.59, P = .036) and age (OR 1.023, 95%CI 1.01-1.05, P = .033). CONCLUSION: The results confirm late diagnosis, a lower than expected prevalence and risk of ASCVD, a higher than expected prevalence of type 2 diabetes and undertreatment, with relatively few patients reaching goals. Recommendations include, the use of combination lipid lowering therapy, control of comorbid conditions and more frequent genetic testing in the future.


Subject(s)
Hyperlipoproteinemia Type II , Adult , Humans , Middle Aged
10.
Bol Med Hosp Infant Mex ; 77(1): 34-37, 2020.
Article in English | MEDLINE | ID: mdl-32115584

ABSTRACT

Background: Epicardial pacemaker is the preferred method for newborns and children under 10 kg of weight. However, its placement presents a high rate of premature failure. Case report: The case of an infant requiring placement of pacemaker by congenital atrioventricular block with prenatal diagnosis is described. The patient showed critical stenosis of the superior vena cava as a complication. Interventional resolution using a stent at the site of stenosis corrected the superior vena cava syndrome effectively. Conclusions: This case represents a clinically viable alternative for the treatment of superior vena cava syndrome, which can be used after other conventional therapies have failed.


Introducción: El marcapasos epicárdico es el método preferido en recién nacidos y niños que pesan menos de 10 kg. Sin embargo, su colocación cuenta con una alta incidencia de fracaso prematuro. Caso clínico: Se presenta el caso de un lactante que requirió la colocación de un marcapasos por bloqueo atrioventricular congénito diagnosticado prenatalmente. El paciente presentaba estenosis crítica de la vena cava superior como complicación secundaria a los cables del marcapasos. La resolución intervencionista mediante un stent en el sitio de estenosis corrigió el síndrome de vena cava superior de forma efectiva. Conclusiones: Este caso representa una alternativa clínicamente viable en el tratamiento del síndrome de vena cava superior, que puede emplearse después de otras terapias convencionales que hayan fallado.


Subject(s)
Atrioventricular Block/therapy , Pacemaker, Artificial , Stents , Superior Vena Cava Syndrome/surgery , Atrioventricular Block/congenital , Female , Humans , Infant , Superior Vena Cava Syndrome/etiology , Vena Cava, Superior/pathology
11.
Bol. méd. Hosp. Infant. Méx ; 77(1): 34-37, ene.-feb. 2020. graf
Article in Spanish | LILACS | ID: biblio-1153227

ABSTRACT

Resumen Introducción: El marcapasos epicárdico es el método preferido en recién nacidos y niños que pesan menos de 10 kg. Sin embargo, su colocación cuenta con una alta incidencia de fracaso prematuro. Caso clínico: Se presenta el caso de un lactante que requirió la colocación de un marcapasos por bloqueo atrioventricular congénito diagnosticado prenatalmente. El paciente presentaba estenosis crítica de la vena cava superior como complicación secundaria a los cables del marcapasos. La resolución intervencionista mediante un stent en el sitio de estenosis corrigió el síndrome de vena cava superior de forma efectiva. Conclusiones: Este caso representa una alternativa clínicamente viable en el tratamiento del síndrome de vena cava superior, que puede emplearse después de otras terapias convencionales que hayan fallado.


Abstract Background: Epicardial pacemaker is the preferred method for newborns and children under 10 kg of weight. However, its placement presents a high rate of premature failure. Case report: The case of an infant requiring placement of pacemaker by congenital atrioventricular block with prenatal diagnosis is described. The patient showed critical stenosis of the superior vena cava as a complication. Interventional resolution using a stent at the site of stenosis corrected the superior vena cava syndrome effectively. Conclusions: This case represents a clinically viable alternative for the treatment of superior vena cava syndrome, which can be used after other conventional therapies have failed.


Subject(s)
Female , Humans , Infant , Pacemaker, Artificial , Superior Vena Cava Syndrome/surgery , Stents , Atrioventricular Block/therapy , Vena Cava, Superior/pathology , Superior Vena Cava Syndrome/etiology , Atrioventricular Block/congenital
12.
Arch. cardiol. Méx ; Arch. cardiol. Méx;87(1): 13-17, ene.-mar. 2017.
Article in English | LILACS | ID: biblio-887489

ABSTRACT

Abstract: Objective: REMEHIP is a prospective, multicentre registry on pulmonary hypertension. The main objective will be to identify the clinical profile, medical care, therapeutic trends and outcomes in adult and pediatric Mexican patients with well-characterized pulmonary hypertension. Methods: REMEHIP a multicenter registry began in 2015 with a planned recruitment time of 12 months and a 4-year follow-up. The study population will comprise a longitudinal cohort study, collecting data on patients with prevalent and incident pulmonary hypertension. Will be included patients of age >2 years and diagnosis of pulmonary hypertension by right heart catheterization within Group 1 and Group 4 of the World Health Organization classification. The structure, data collection and data analysis will be based on quality current recommendations for registries. The protocol has been approved by institutional ethics committees in all participant centers. All patients will sign an informed consent form. Currently in Mexico, there is a need of observational registries that include patients with treatment in the everyday clinical practice so the data could be validated and additional information could be obtained versus the one from the clinical trials. In this way, REMEHIP emerges as a link among randomized clinical trials developed by experts and previous Mexican experience.


Resumen: Objetivo: REMEHIP es un registro prospectivo, multicéntrico en hipertensión pulmonar. El objetivo principal será identificar el perfil clínico, atención médica, tendencias terapéuticas y evolución en pacientes mexicanos adultos y pediátricos con hipertensión pulmonar bien caracterizada. Métodos: El REMEHIP comenzó en el año de 2015 y se planea un reclutamiento de 12 meses con un seguimiento de 4 años. La población en estudio será una cohorte longitudinal y se obtendrán datos de pacientes prevalentes e incidentes con hipertensión pulmonar. Se incluirán pacientes con edad > 2 años con diagnóstico de hipertensión pulmonar demostrado por cateterismo cardiaco derecho del Grupo 1 y Grupo 4 de la clasificación de la Organización Mundial de la Salud. La estructura, colección de datos y el análisis se establecerá a través de las recomendaciones actuales de calidad para los registros. El protocolo ha sido aprobado por los comités de ética de todos los centros participantes. Todos los pacientes firmarán un consentimiento informado. Actualmente en México existe una necesidad de registros observacionales que incluyan a pacientes con tratamiento en la práctica clínica cotidiana, de tal forma que los datos obtenidos podrían validarse y el resto de la información podría compararse con la derivada de los estudios clínicos. De esta forma REMEHIP surge como un vínculo entre los estudios clínicos aleatorizados conducidos por expertos y la experiencia mexicana previa.


Subject(s)
Humans , Registries , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/therapy , Research Design , Prospective Studies , Mexico
13.
Arch Cardiol Mex ; 87(1): 13-17, 2017.
Article in English | MEDLINE | ID: mdl-27988223

ABSTRACT

OBJECTIVE: REMEHIP is a prospective, multicentre registry on pulmonary hypertension. The main objective will be to identify the clinical profile, medical care, therapeutic trends and outcomes in adult and pediatric Mexican patients with well-characterized pulmonary hypertension. METHODS: REMEHIP a multicenter registry began in 2015 with a planned recruitment time of 12 months and a 4-year follow-up. The study population will comprise a longitudinal cohort study, collecting data on patients with prevalent and incident pulmonary hypertension. Will be included patients of age >2 years and diagnosis of pulmonary hypertension by right heart catheterization within Group 1 and Group 4 of the World Health Organization classification. The structure, data collection and data analysis will be based on quality current recommendations for registries. The protocol has been approved by institutional ethics committees in all participant centers. All patients will sign an informed consent form. Currently in Mexico, there is a need of observational registries that include patients with treatment in the everyday clinical practice so the data could be validated and additional information could be obtained versus the one from the clinical trials. In this way, REMEHIP emerges as a link among randomized clinical trials developed by experts and previous Mexican experience.


Subject(s)
Hypertension, Pulmonary , Registries , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/therapy , Mexico , Prospective Studies , Research Design
14.
Ginecol Obstet Mex ; 82(8): 518-22, 2014 Aug.
Article in Spanish | MEDLINE | ID: mdl-25282943

ABSTRACT

BACKGROUND: Treatments for cervical lesions through the years have been varied, from cauterization with chemicals, to the use of electrosurgery with diathermic loop, however the method to be chosen should be one that offers greater benefits and lower risks. OBJECTIVE: Present a well structured study protocol in patients presenting with cervical disease and offer treatment cryotherapy as ablative method of choice in this group of patients and returning this widely known process, but nevertheless had been relegated. MATERIAL AND METHOD: By an analytical and descriptive retrospective study and treatment of one thousand patients with cervical pathology in the course of 20 years, in which in addition to the drug treatment of individual patients, treatment was performed as ablative cryosurgery cervical is reported, having obtained very good results. RESULTS: With ablative treatment indicated the problem of all' patients resolved, having had a very satisfactory in the short, medium and long term, have had no significant morbidity, thus fulfilling the stated objective. CONCLUSION: Research carried out shows that the surgical procedure performed in carefully selected patients with cervical pathology coursing was appropriate because the results thus demonstrated.


Subject(s)
Cryosurgery , Uterine Cervical Diseases/surgery , Adolescent , Adult , Aged , Female , Gynecologic Surgical Procedures/methods , Humans , Middle Aged , Retrospective Studies , Young Adult
15.
Bioorg Med Chem Lett ; 24(14): 3069-72, 2014 Jul 15.
Article in English | MEDLINE | ID: mdl-24878192

ABSTRACT

A family of 15 N-substituted phenothiazines was designed, synthesized and their acaricidal activity against Rhipicephalus microplus was determined in vitro. The synthetic methodology is simple and can be employed in multigram scale. The rationale for the structure-based design of these compounds is the potential for azines and phenothiazine to engage in π-π interactions; these fragments, joined together by a short, flexible alkoxide linker, structurally resemble phenothiazine-based cholinesterase inhibitors, while their weak basicity implies a neutral active form, rather than a cationic one, thus facilitating penetration of the cuticle of ticks. One compound displayed excellent acaricidal activity (LD50=0.58 µg/mL). Preliminary SAR analysis suggests that the activity is influenced by the presence of a weakly basic nitrogen atom, as well as the substitution pattern within the heterocycles.


Subject(s)
Drug Design , Phenothiazines/pharmacology , Rhipicephalus/drug effects , Tick Control , Animals , Dose-Response Relationship, Drug , Molecular Structure , Phenothiazines/chemical synthesis , Phenothiazines/chemistry , Structure-Activity Relationship
16.
Ginecol Obstet Mex ; 80(10): 654-8, 2012 Oct.
Article in Spanish | MEDLINE | ID: mdl-23240229

ABSTRACT

BACKGROUND: Uterine fibroids are the most common tumors of the uterus, their distribution in anatomical layers and segments of it are very varied clinical manifestations are usually abnormal bleeding and known treatments, the surgery is the most accomplished, either myomectomy or hysterectomy by both endoscopy and laparotomy, transvaginal approach is less common, but consider it a right way and solving the problem in selected cases. OBJECTIVE: To present a well-defined study protocol in patients with abnormal uterine bleeding, and myomectomy as a surgical transcervical simple, safe and effective in patients with intracavitary myoma protruded through the cervical canal. MATERIAL AND METHODS: ten patients are presented with abnormal uterine bleeding and anemia of various degrees, studied over a period of two years, following a research protocol for clinical methods, cabinet and laboratory diagnosis was submucosal fibroids with single fibroid, pedunculated protruding a vagina, treatment was performed transcervical myomectomy. RESULTS: The surgical procedure was obtained by solving the problem, having found the ten patients in the subsequent revisions in the outpatient, asymptomatic and without tumor lesions in the uterus. CONCLUSIONS: This study shows that performing a notarization in patients with abnormal uterine bleeding and making appropriate surgical treatment, achieves the desired objectives.


Subject(s)
Gynecologic Surgical Procedures/methods , Leiomyomatosis/surgery , Uterine Neoplasms/surgery , Adult , Anemia/etiology , Anemia/therapy , Blood Transfusion , Cervix Uteri , Electrocoagulation , Female , Humans , Leiomyomatosis/diagnostic imaging , Ligation , Middle Aged , Tumor Burden , Ultrasonography , Uterine Hemorrhage/etiology , Uterine Neoplasms/diagnostic imaging , Young Adult
17.
Ginecol Obstet Mex ; 75(8): 484-7, 2007 Aug.
Article in Spanish | MEDLINE | ID: mdl-18293679

ABSTRACT

A clinical case of a patient with a giant tumoration of the ovary appears, that went to the external consultation declaring progressive picture of abdominal distension, postprandial fullness and general weakness. The diagnosis was elaborated as much by clinical and paraclinical methods (USG and RX) as well as by pathological anatomy; and the handling consisted firstly of puncture-drainage and later by laparotomy with the extraction of the same one. The gross weight of the tumoration was of 38 kg and the histopathologic study was of cystoadenoma serum giant of the left ovary. Evolution of the patient was satisfactory having a favorable prognosis, returning normally to her habitual activities.


Subject(s)
Cystadenoma/pathology , Ovarian Neoplasms/pathology , Adult , Female , Humans , Organ Size
18.
Ginecol Obstet Mex ; 74(3): 153-7, 2006 Mar.
Article in Spanish | MEDLINE | ID: mdl-16886757

ABSTRACT

This report is about one of the main frequent causes of mother mortality, with the main purpose of creating conscience and alerting to medical population about the importance of the adequate and opportune cardiology and obstetric diagnosis and treatment. Also refers the main hemodynamic changes in pregnant woman, the risk of death according to the specific suffering, and the obstetric and cardiological control parameters; trying to diminish as much as possible the perinatal and mother mortality.


Subject(s)
Heart Diseases , Pregnancy Complications, Cardiovascular , Female , Heart Diseases/therapy , Humans , Pregnancy , Pregnancy Complications, Cardiovascular/therapy
SELECTION OF CITATIONS
SEARCH DETAIL